Amgen 2012 Annual Report Download - page 4

Download and view the complete annual report

Please find page 4 of the 2012 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 150

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com
© 2013 Amgen Inc. All rights reserved.
Forward-looking statements: This communication contains forward-looking statements that are based on Amgen management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and assumptions
that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including plans for the growth of our
business and other financial metrics; expected clinical or regulatory results or practices; development of Amgen’s product candidates, including anticipated regulatory filings; our manufacturing capabilities; and planned international
expansion. Forward-looking statements involve significant risks and uncertainties, including those more fully described in the Risk Factors found in the Form 10-K for the year ended December 31, 2012 (provided with this
communication) and in the most recent periodic reports on Form 10-Q and Form 8-K filed by Amgen with the U.S. Securities and Exchange Commission, and actual results may vary materially. Except where otherwise indicated, Amgen
is providing this information as of March 19, 2013, and does not undertake any obligation to update any forward-looking statements contained in this Annual Report as a result of new information, future events, or otherwise.
Reconciliation of GAAP Earnings Per Share to “Adjusted” Earnings Per Share (Unaudited)
(a) The above adjustments are presented net of their related per-share tax impact of $0.42 and $0.38 for 2012 and 2011, respectively.
(b) Includes tax expense/(benefit) related to certain prior-period items excluded from “Adjusted” earnings.
Results for the years ended December 31, 2012 2011
GAAP earnings per share (diluted) $5.52 $4.04
Adjustments to GAAP earnings per share(a):
Restructuring/cost-savings initiatives 0.31 0.12
Non-cash amortization of product technology rights acquired in a prior year business combination 0.24 0.20
Acquisition-related expenses 0.18 0.04
Non-cash interest expense associated with our convertible notes 0.11 0.10
Expenses related to various legal proceedings 0.07 0.78
Stock option expense 0.05 0.06
Tax net expense/(benefit)(b) 0.03 (0.01)
“Adjusted” earnings per share (diluted) $6.51 $5.33